Cost-Effectiveness Analysis of Fulvestrant in the Treatment of Metastatic Breast Cancer in Second-Line Chemotherapy

Cost Effectiveness ◽

Metastatic Breast ◽

Second Line ◽

Effectiveness Analysis ◽

Cost-Effectiveness Analysis of Adding Palbociclib as a Second-Line Endocrine Therapy for HR+/HER2– Metastatic Breast Cancer From the US and Chinese Perspectives

Clinical Therapeutics ◽

10.1016/j.clinthera.2019.04.033 ◽

2019 ◽

Vol 41 (6) ◽

pp. 1175-1185 ◽

Cited By ~ 5

Author(s):

Yingjie Zhang ◽

Xiaohui Zeng ◽

Haijun Deng ◽

Fang Ma ◽

Ye Peng ◽

...

Keyword(s):

Breast Cancer ◽

Cost Effectiveness ◽

Endocrine Therapy ◽

Metastatic Breast ◽

Second Line ◽

Effectiveness Analysis ◽

The Us

PCN69 Cost-Effectiveness Analysis of NOVEL Therapies for HER2+ Metastatic Breast Cancer: [FAM-] Trastuzumab Deruxtecan Versus Tucatinib Trastuzumab and Capecitabine Combination

Value in Health ◽

10.1016/j.jval.2020.08.206 ◽

2020 ◽

Vol 23 ◽

pp. S433-S434

Author(s):

G. Vondeling ◽

E. Palaka ◽

C. Livings ◽

J. Naik ◽

W. Sullivan

Keyword(s):

Breast Cancer ◽

Cost Effectiveness ◽

Metastatic Breast ◽

Novel Therapies ◽

Erratum to: Cost-effectiveness analysis of everolimus plus exemestane versus exemestane alone for treatment of hormone receptor positive metastatic breast cancer

Breast Cancer Research and Treatment ◽

10.1007/s10549-014-3107-3 ◽

2014 ◽

Vol 147 (2) ◽

pp. 443-443 ◽

Cited By ~ 1

Author(s):

Vakaramoko Diaby ◽

Georges Adunlin ◽

Simon B. Zeichner ◽

Kiran Avancha ◽

Gilberto Lopes ◽

...

Keyword(s):

Breast Cancer ◽

Cost Effectiveness ◽

Hormone Receptor ◽

Metastatic Breast ◽

Hormone Receptor Positive ◽

Abstract PS13-31: Prospective observational study to explore the effectiveness of eribulin as first- or second- line chemotherapy in patients with HER2-negative hormone-resistant advanced or metastatic breast cancer (KBCRN A001: E-SPEC study)

10.1158/1538-7445.sabcs20-ps13-31 ◽

2021 ◽

Author(s):

Yuri Fujimoto ◽

Yuichiro Kikawa ◽

Takeshi Kotake ◽

Shigeru Tsuyuki ◽

Sachiko Takahara ◽

...

Keyword(s):

Breast Cancer ◽

Observational Study ◽

Prospective Observational Study ◽

Metastatic Breast ◽

Second Line ◽

230 A Phase II Study of Pegylated Liposomal Doxorubicin Combined with Cyclophosphamide / 5-fluorouracil as Second Line Chemotherapy in Patients with Metastatic Breast Cancer Who Failed Previous Taxane-based Treatment

European Journal of Cancer ◽

10.1016/s0959-8049(12)70298-8 ◽

2012 ◽

Vol 48 ◽

pp. S109-S110

Author(s):

H.K. Chang ◽

Y.C. Lin ◽

K.M. Rau ◽

Y.Y. Chen ◽

K.D. Lee ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Liposomal Doxorubicin ◽

Phase Ii Study ◽

Metastatic Breast ◽

Pegylated Liposomal Doxorubicin ◽

Second Line ◽

A phase II trial of docetaxel (Taxotere®) as second-line chemotherapy in patients with metastatic breast cancer

Journal of Cancer Research and Clinical Oncology ◽

10.1007/s00432-007-0259-0 ◽

2007 ◽

Vol 134 (2) ◽

pp. 125-135 ◽

Cited By ~ 9

Author(s):

Martina Baur ◽

Allan T. van Oosterom ◽

Véronique Diéras ◽

Michele Tubiana-Hulin ◽

R. Charles Coombes ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Metastatic Breast ◽

Second Line ◽

First-line fulvestrant plus anastrozole for hormone-receptor-positive metastatic breast cancer in postmenopausal women: a cost-effectiveness analysis

Breast Cancer ◽

10.1007/s12282-019-01034-6 ◽

2019 ◽

Vol 27 (3) ◽

pp. 399-404 ◽

Cited By ~ 1

Author(s):

Weiting Liao ◽

Jiaxing Huang ◽

Qiuji Wu ◽

Feng Wen ◽

Nan Zhang ◽

...

Keyword(s):

Breast Cancer ◽

Cost Effectiveness ◽

Postmenopausal Women ◽

Hormone Receptor ◽

Metastatic Breast ◽

First Line ◽

Hormone Receptor Positive ◽

Cost-effectiveness analysis of routine use of eribulin in patients with metastatic breast cancer in France: A retrospective analysis.

Journal of Clinical Oncology ◽

10.1200/jco.2014.32.15_suppl.e11531 ◽

2014 ◽

Vol 32 (15_suppl) ◽

pp. e11531-e11531

Author(s):

Marie-Justine Paillard ◽

Elsa Curtit ◽

Virginie Nerich ◽

Laurent Cals ◽

Fernando Bazan ◽

...

Keyword(s):

Breast Cancer ◽

Cost Effectiveness ◽

Retrospective Analysis ◽

Metastatic Breast ◽

A phase II, multicenter, single-arm trial of eribulin as first or second line chemotherapy for HER2-negative advanced or metastatic breast cancer: Evaluation of efficacy, safety, and patient-reported outcomes.

Journal of Clinical Oncology ◽

10.1200/jco.2018.36.15_suppl.e13059 ◽

2018 ◽

Vol 36 (15_suppl) ◽

pp. e13059-e13059 ◽

Cited By ~ 2

Author(s):

Mitsuhiko Iwamoto ◽

Kosei Kimura ◽

Satoru Tanaka ◽

Daigo Yamamoto ◽

Katsuhide Yoshidome ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Patient Reported Outcomes ◽

Metastatic Breast ◽

Second Line ◽

Patient Reported ◽

Cost Effectiveness Analysis of Eribulin Mesylate as a Treatment for Metastatic Breast Cancer In Spain: Management in the Later Lines of Therapy

Value in Health ◽

10.1016/j.jval.2015.03.1175 ◽

2015 ◽

Vol 18 (3) ◽

pp. A203 ◽

Cited By ~ 1

Author(s):

U. Majethia ◽

G. Tremblay ◽

I. Kontoudis ◽

J. DeRosendo

Keyword(s):

Breast Cancer ◽

Cost Effectiveness ◽

Metastatic Breast ◽

Eribulin Mesylate ◽